SCHEMBL22925935

SCHEMBL22925935

N#Cc1cnc(Nc2ncc(-c3ccc(C(F)(F)F)cn3)o2)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 6/20 0.38
TRPV1 Q8NER1 7/20 0.37
NPSR1 Q6W5P4 2/20 0.37
KDM4E B2RXH2 1/20 0.37
KDR P35968 4/20 0.36
FLT1 P17948 3/20 0.36
FLT4 P35916 2/20 0.36
NUAK1 O60285 1/20 0.36
CHEK2 O96017 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
MARK3 P27448 1/20 0.36
FLT3 P36888 1/20 0.36
CLK2 P49760 1/20 0.36
RPS6KA3 P51812 1/20 0.36
PRKAG1 P54619 1/20 0.36
KCNH2 Q12809 1/20 0.36
PRKAA1 Q13131 1/20 0.36
PRKD1 Q15139 1/20 0.36
RPS6KA1 Q15418 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22926090 0.87 TRPV1 (0.48) CHEK1TRPV1KDRFLT1FLT4
SCHEMBL24636937 0.85 NPSR1 (0.39) TRPV1NPSR1KDM4EKDRFLT1
SCHEMBL29620869 0.85 NPSR1 (0.39) TRPV1NPSR1KDM4EKDRFLT1
SCHEMBL22925932 0.84 CHEK1 (0.39) CHEK1NPSR1KDM4EKDRFLT1
SCHEMBL22925966 0.82 CHEK1 (0.41) CHEK1KDRFLT1FLT4CHEK2
SCHEMBL22925610 0.80 CASP3 (0.43) CHEK1TRPV1NPSR1KDM4EKDR
SCHEMBL24637089 0.79 NPSR1 (0.38) TRPV1NPSR1KDM4EKDRFLT1
SCHEMBL28733779 0.77 TRPV1 (0.36) TRPV1NPSR1KDM4EKDRRPS6KA3
SCHEMBL22925597 0.76 KMT2A (0.37) TRPV1NPSR1KDM4E
SCHEMBL22925790 0.76 KMT2A (0.37) TRPV1NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114450281-B Inhibitor compounds 辛塞拉治疗私人有限公司 2024-08-16 CN disclosed
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 US disclosed
EP-4003986-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-06-01 EP disclosed
CN-114450281-A Inhibitor compounds 辛塞拉治疗私人有限公司 2022-05-06 CN disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB CHEK1 1509/4885TRPV1 4690/4885NPSR1 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.